Impacts of FDA Approval and Medicare Restriction on Antiamyloid Therapies for Alzheimer’s Disease: Patient Outcomes, Healthcare Costs, and Drug Development, Rouen Brockmann, Joanna Nixon, Bryan L. Love Pharm D., Ismaeel Yunusa Ph. D.
Faculty Publications